Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.

Inclusion Criteria: * Man or woman aged 16-80 years, * Patient presenting 6 or more episodes of orofacial herpes infections during the preceding 12-months' period (prior to the study entry), * Woman of childbearing age under effective contraception, * Patient reporting a current stable sexual relationship (steady sexual partner during study duration), * Patient having faculties to understand and respect the constraints of the study, * Signature of the Informed Consent Form. Exclusion Criteria: * Pregnant or breastfeeding woman, * Patient under immunotherapy (including immunosuppressive treatment) or micro-immunotherapy received during last previous 6 months, * Patient who had a suppressive antiviral therapy during last month, * Patient who wishes to continue his/her suppressive antiviral therapy, * Patient with known lactose intolerance, * Patient who participated in a clinical study in the previous 3-month period, * Patient who is not sufficiently motivated to engage in a follow-up period of 12 months, or likely to travel or to move before the end of the study, * Patient with severe immunodeficiency disease requiring long term treatment (\*) or under chemotherapy or radiotherapy or corticoid therapy, * Patient under listed homeopathic or phytotherapy treatment, * Patient using or addicted to recreational drugs. (\*) important renal or respiratory insufficiency, transplanted or grafted patients HIV/AIDS, terminal cancer.